M1FG
ACAD icon

Mach-1 Financial Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Mach-1 Financial Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,726
Closed -$461K – 79
2023
Q4 		$461K Buy
+14,726
New +$352K 0.17% 137

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Mach-1 Financial Group's ACAD Position: Q1 2024 in Review

Mach-1 Financial Group sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 14,726 shares — an estimated $461K sold.

Mach-1 Financial Group first reported a position in ACAD in Q4 2023 and held it in 1 quarter. The position peaked at $461K in Q4 2023. 267 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

  • Mach-1 Financial Group reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Mach-1 Financial Group sold 14,726 Acadia Pharmaceuticals shares in Q1 2024, an estimated $461K.
  • Mach-1 Financial Group first reported a position in Acadia Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Mach-1 Financial Group's Acadia Pharmaceuticals position peaked at $461K in Q4 2023.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Mach-1 Financial Group's 13F filing for Q1 2024, filed 10 May 2024.